Establishing a new paradigm in clinically effective microbiome therapy

Research and IP

New basic concepts in microbiome management and ecology including targeted organisms, multi-organism (systems) strategies, computational microbiomics, and support environment/matrix strategies


Product lines that satisfy medical practice, reimbursement, patient requirement, and public health objectives, while reducing disease recurrence and care provider liability/risk/matrix strategies

Product Development

Initially, efficacious and cost-effective, user-appropriate anti-MRSA and v-MSSA products for hospital, outpatient, and consumer environments

Our Company

BioPlx is an advanced microbiomics company developing non-antibiotic methods for the control of infectious disease, including multiple-drug resistant “super-bugs”. The company employs targeted microbiological agents to create unique interventional formulations.

BioPlx is initially focused on control of hospital (HA) and community acquired (CA) dermal (exobiomic) disease, particularly:

  • MRSA - (methicillin-resistant S. aureus)
  • v-MSSA (virulent - methicillin-susceptible S. aureus)

With an emphasis on preventing recurrence and re-infection.


Innovations that deliver clinically effective microbiomics

Exobiome™ Ecology

Map functional intra-biome relationships to create transitional -> stable desired populations

Computational Biomics

Very high capacity computational and analytic methods to extract and correlate global data sets

Biota Development

Development of specialized organisms with known attributes to occupy specific biome niches

Formulation Components

Additional nutrient, signaling, and selective agents included to improve biome management

Support Matrix

Materials and structures used to contain, sustain, preserve, and administer biome formulations

Product Attributes

Handling and product use characteristics required for HA, OP, and CA market segments

How It's Done

BioPlx is a highly connected global organization, led by an exceptionally qualified management team and board with deep technical, entrepreneurial, and business experience. The company makes maximum use of new information and computational technologies to achieve cutting-edge technical and business strategies. The organization is designed to use both in-house and proprietary contract development and consulting strategies across the wide range of components and methods incorporated within this product line


Innovations that move the needle on clinically effective microbiomics

2017 BioPlx01-WT

A methodology and organism to prevent the recurrence of Methicillin Resistant Staphylococcus Aureus (MRSA) and Virulent Methicillin Susceptible Staphhylococcus Aureus (vMSSA)

Rooted in the discovery of fundamental principles of how durable integration into a host microbiome can be achieved, initial clinical data shows exceptional effectiveness in preventing the recurrence of MRSA in medical workers

2019 BioPlx01-KS

An evolution of the groundbreaking BioPlx01-WT, this organism incorporates breakthrough technology designed to prevent the organism from being able to become an accidental pathogen to its host.

Pre-clinical data shows the complete functionality of the unique safety characteristics of this organism without compromising its effectiveness at preventing the recurrence of MRSA or vMSSA.

2020 BioPlx02

S. Epidermidis is sometimes described as a benign commensal, however the organism is a leading cause of infection in indwelling line and dialysis patients

BioPlx plans to expand its platform technology to enable a new paradigm in preventing Staphylococcus Epidermidis (S. Epidermidis) associated infections

2020 and beyond

Additional Indications and Pathogens

Further development of the platform into other lines of microbes outside Staphylococcus, including E. Coli that causes urinary tract infections, Acne, and other dermal, mucosal, or gastrointestinal pathogens

Contact BioPlx

We are looking for strategic partners. Reach out and let's do amazing things together.

Corporate HQ:

BioPlx, Inc.

5777 Central Ave #110

Boulder, CO 80301



BioPlx Microbiomics Pvt. Ltd.

A-89 Defence Colony, Mawana Road

Ganganagar, Meerut 250001